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Abstract
The C-type lectin domain family 12, member A (CLEC12A) receptor has emerged as
a leukaemia-associated and cancer stem cell marker in myeloid malignancies. How-
ever, a detailed delineation of its expression in normal haematopoiesis is lacking.
Here, we have characterized the expression pattern of CLEC12A on the earliest
stem- and myeloid progenitor subsets in normal bone marrow. We demonstrate dis-
tinct CLEC12A expression in the classically defined myeloid progenitors, where on
average 39.1% (95% CI [32.5;45.7]) of the common myeloid progenitors (CMPs)
expressed CLEC12A, while for granulocyte-macrophage progenitors and megakary-
ocyte-erythroid progenitors (MEPs), the average percentages were 81.0% (95% CI
[76.0;85.9]) and 11.9% (95% CI [9.3;14.6]), respectively. In line with the reduced
CLEC12A expression on MEPs, functional assessment of purified CLEC12A+/
CMPs and MEPs in the colony-forming unit assay demonstrated CLEC12A+ subsets
to favour non-erythroid colony growth. In conclusion, we provide evidence that the
earliest CLEC12A+ cell in the haematopoietic tree is the classically defined CMP.
Furthermore, we show that CLEC12A-expressing CMPs and MEPs are functionally
different than their negative counterparts. Importantly, these data can help deter-
mine which cells will be spared during CLEC12A-targeted therapy, and we propose
CLEC12A to be included in future studies of myeloid cancer stem cell biology.
K E YWORD S
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1 | INTRODUCTION
The transmembrane receptor C-type lectin domain family 12, mem-
ber A (CLEC12A) is emerging as a marker of blasts and leukaemic
stem cells (LSC) in acute myeloid leukaemia (AML) and by inference
as a useful tool in both the diagnostic and follow-up settings.1-5 In
addition, we have recently shown the relevance of this marker in the
context of myelodysplastic syndrome (MDS).6 In the setting of malig-
nant haematology, one of the most appealing features of CLEC12A
is its lack of expression on CD34+CD38 cells in normal bone mar-
row (BM), regenerating BM and G-CSF-stimulated peripheral bloodPeter Hokland and Line Nederby contributed equally to this work.
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stem cells,2 making it a potential treatment target. Recent ventures
in this regard include the development of anti-CD3/anti-CLEC12A
bispecific antibodies.7-9 The upcoming roles of CLEC12A as a cancer
stem cell marker and potential treatment target emphasize the need
of knowing the details of its expression pattern on early stem and
progenitor cells in healthy individuals.
Although the classical roadmap of haematopoiesis is constantly
being revised,10-12 it is nevertheless providing a powerful tool for
understanding the production of mature circulating blood cells and
continuously serves as a solid model for studying clonal evolution in
the myeloid spectrum of haematological malignancies.13-16 In this
study, we opted to employ the immunophenotypic definition of the
haematopoietic stem cell (HSC) as being Lin-CD34+CD38CD90+
CD45RA,17-19 the multipotent progenitor (MPP) as being Lin-
CD34+CD38CD90CD45RA20 and the human multilymphoid
progenitor (MLP, also termed lymphoid-primed multipotent progeni-
tor) as Lin-CD34+CD38CD90/lowCD45RA+.21 With respect to the
Lin-CD34+CD38+ myeloid progenitors, we distinguished the common
myeloid progenitor (CMP), the granulocyte-macrophage progenitor
(GMP) and the megakaryocyte-erythroid progenitor (MEP) subsets
based on their CD123 and CD45RA expression as first described by
Manz and colleagues.22
Using these definitions, we have delineated the expression of
CLEC12A on normal BM stem- and myeloid progenitor cells and
evaluated the influence of this marker on the growth of purified
CMPs, GMPs and MEPs in the colony-forming cell assay. Impor-
tantly, our results provide evidence that the earliest CLEC12A+ cell
in normal haematopoiesis is the classically defined CMP.
2 | METHODS
2.1 | Bone marrow samples
Bone marrow samples (n = 13) from healthy volunteers were obtained
in the setting of BM harvest for allogeneic BM transplantation or
donated as part of the anonymous biobank for normal donors in
Hemodiagnostic Laboratory, Department of Hematology, Aarhus
University Hospital. The biobank is approved by the local Ethics Com-
mittee of the Central Denmark Region, and sample collection was per-
formed after informed consent was given. Mononuclear cells (MNCs)
were obtained by Lymphoprep (Axis-Shield plc., Dundee, Scotland)
separation according to the manufacturer’s instructions, cryopreserved
in 10% dimethylsulphoxide and stored in liquid nitrogen.
2.2 | Flow cytometry
Cryopreserved MNCs were thawed in 37°C water bath and resus-
pended in RoboSep Buffer (StemCell Technologies, Vancouver, BC,
Canada) with 15% heat-inactivated foetal calf serum (Biochrom,
GmbH, Berlin, Germany). Subsequently, cells were stained with the
monoclonal antibodies (MoAb) listed in Table 1. Lineage depletion
was accomplished by introducing a dump channel with lineage-
MoAbs. Data acquisition was performed on a Navios flow cytometer
(Donor 1-9) (Beckman-Coulter, Inc., Brea, CA, USA) equipped with
three lasers; 405 nm, 488 nm and 638 nm, respectively. Compensa-
tion was set using with UltraComp eBeads (eBioscience, San Diego,
CA, USA) together with the relevant fluorochrome-conjugated anti-
bodies. Data were analysed with FlowJo Data Analysis Software,
version X (FlowJo, Ashland, OR, USA). For each sample and for each
fluorochrome, positive and negative gates were determined by
means of fluorescence minus one (FMO) controls.
The gating strategy used for analysing the myeloid progenitor cells
is depicted in Figure 1. In short, the lineage negative singlets were
defined (not shown) and displayed in a CD34 vs. CD38 plot. Herein,
the CD34+CD38+ cell subset was defined (Figure 1A) and the progeni-
tors were further enriched by CD90 negativity (Figure 1B). The CMPs
were defined as being Lin-CD34+CD38+CD90CD123+CD45RA,
GMPs as Lin-CD34+CD38+CD90CD123+CD45RA+ and MEP as Lin-
CD34+CD38+CD90CD123CD45RA (Figure 1C). Next, these three
myeloid progenitor subsets were further gated by their CLEC12A
expression (Figure 1D). The gating strategy used for analysing
CLEC12A expression on HSCs, MPPs and MLPs in the Lin-
CD34+CD38 subset is depicted in Figure S1. The number of analysed
events and the corresponding percentages of CLEC12A+ cells are
given in Table S1.
2.3 | Fluorescence-activated cell sorting
Cryopreserved BM MNCs from 6 donors (D1, D2, D10, D11, D12
and D13) were thawed and stained with the MoAbs listed in
TABLE 1 Applied fluorochrome-conjugated monoclonal antibodies
MoAb Fluorochrome Clone #Cat Company
CD45RA FITC HI100 304106 BioLegend
CLEC12A PE HB3 Own lab
CD38 ECD LS198.4.3 A99022 BC
CD2 PE-Cy5 RPA-2.10 300209 BioLegend
CD3 PE-Cy5 HIT3a 300309 BioLegend
CD4 PE-Cy5 RPA-T4 300509 BioLegend
CD7 PE-Cy5 CD7-6B7 343110 BioLegend
CD8a PE-Cy5 RPA-T8 301009 BioLegend
CD10 PE-Cy5 HI10a 312206 BioLegend
CD11b PE-Cy5 ICRF44 301307 BioLegend
CD14 PE-Cy5 RMO52 A07765 BC
CD19 PE-Cy5 HIB19 302209 BioLegend
CD20 PE-Cy5 2H7 302307 BioLegend
CD56 PE-Cy5 B159 555517 BD
CD235a PE-Cy5 HIR2 306605 BioLegend
CD123 PE-Cy7 6H6 306010 BioLegend
CD34 APC BIRMA-K3 C7238 DAKO
CD90 BV421 5E10 328122 BioLegend
FITC, fluorescein-isothiocyanate; PE, phycoerythrin; ECD: PE-Texas Red
PE-Cy5: phycoerythrin-cyanine5; PE-Cy7, phycoerythrin-cyanine7; APC,
allophycocyanin; BV421, brilliant violet 421. BD, BD Biosciences; BC,
Beckman-Coulter.
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Table 1. Fluorescence-activated cell sorting was performed on a BD
FACSAriaTM III (BD Biosciences) equipped with four lasers; 405 nm,
488 nm, 561 nm and 633 nm, respectively. Using the same gating
strategy as described above, the CMPs, GMPs and MEPs were
sorted into CLEC12A+/ subsets, respectively. Due to the rarity of
the sorted cell populations, post-sort purity was determined in 21 of
36 cases and reported in Table S2. Flow cytometry data from the
sorting experiments (Donor 10-13) were included in the overall anal-
yses of CLEC12A expression on myeloid progenitors.
2.4 | Colony-forming cell assay
Up to 500 sorted cells from subsets representing CLEC12A+/
CMPs, GMPs and MEPs were seeded in 35-mm discs in 1 ml of
MethoCult H4435 (StemCell Technologies) supplemented with peni-
cillin-streptomycin (Gibco, Thermo Fischer Scientific Inc.) and
allowed to incubate for 14 days at 37°C, in 95% humidity and 5%
CO2. Whenever possible, cells were seeded in duplicates.
Colony-forming cells were counted and scored by morphology as
burst-forming unit-erythroid (BFU-E), colony-forming unit-erythroid
(CFU-E), colony-forming unit-granulocyte-erythroid-macrophage-
megakaryocyte (CFU-GEMM), colony-forming unit-granulocyte-
macrophage (CFU-GM), colony-forming unit-macrophage (CFU-M),
and colony-forming unit-granulocyte (CFU-G). For the seeded GMPs,
a clear distinction between CFU-GMs, CFU-Ms and CFU-Gs was
possible and colonies were counted as such. For CMPs and MEPs,
the morphology of myeloid colonies was less clear; hence, CFU-
GMs, CFU-Ms and CFU-Gs were counted together as myeloid colo-
nies. The cellular composition of each colony type was verified by
May-Gr€unwald Giemsa staining (Sigma-Aldrich, St. Louis, MO, USA)
of representative colonies cytospun onto slides (n = 1 (donor 1);
data not shown).
2.5 | Statistical analyses
All calculations were conducted in GraphPad Prism version 6 (Graph-
Pad Software, La Jolla, CA, USA). The D’Agostino & Pearson omni-
bus test was used to test whether the percentage of CLEC12A+ cells
F IGURE 1 Gating strategy in the myeloid progenitor compartment. Initially, cells were gated in a forward scatter—side scatter plot, and the
Lin- events were selected (not shown). In the Lin- cell population, the CD34+CD38+ cells were identified (A) and depicted in a CD90 vs. side
scatter plot (B). To further enrich for progenitors, the CD90- cells were selected and depicted in a CD123 vs. CD45RA plot, whereby the
CMP, the GMP and the MEP could be identified (C). These myeloid progenitor subsets were then further gated for their CLEC12A
expression (D)
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followed a Gaussian distribution. For comparison of the CLEC12A+
cell subsets between CMP, GMP and MEP, Student’s unpaired t test
was used. The Mann-Whitney test was applied to test differences in
colony formation in CLEC12A+/ progenitor subsets. A two-sided
P-value < .05 was considered significant.
3 | RESULTS
3.1 | CLEC12A is differentially expressed on
myeloid progenitor subsets
To study at what level in the early human haematopoiesis CLEC12A
is expressed, we employed a seven-colour tube (Table 1) and applied
a stringent negative gating strategy based on FMO controls
(Figure 1, S1). Consistent with previous observations,2 we did not
detect CLEC12A expression on either the HSCs or the MPPs in the
Lin-CD34+CD38 subset (Table S1). For the MLP subset, the num-
ber of events was very low, and thus, it cannot formally be ruled out
that a fraction of these cells could express CLEC12A (Table S1). The
mean percentage of CMPs expressing CLEC12A was 39.1% (95% CI
[32.5;45.7]), while for GMPs and MEPs, the CLEC12A+ fractions
averaged 81.0% (95% CI [76.0;85.9]) and 11.9% (95% CI [9.3;14.6]),
respectively. Hence, the mean percentage of CLEC12A+ CMPs was
significantly different from the mean percentage of CLEC12A+ cells
in GMPs (P < .0001) and MEPs (P < .0001). Also, the mean
CLEC12A+ fractions were significantly different between GMPs and
MEPs (P < .0001) (Table S1, Figure 2A). Notably, the CLEC12A+ cells
were distributed across the whole CMP and GMP compartments
and extended into the MEP compartment (Figure 2B). Taken
together, while CLEC12A is a known marker of mature myeloid
cells,23,24 these data reveal that detectable expression of CLEC12A
emerges at the level of the CMP, and is abundantly expressed on
GMPs and to a lesser extent on the classically defined MEP.
3.2 | Different clonogenic potential in CLEC12A
positive and negative myeloid progenitors
Next, the clonogenic potential of CLEC12A positive and negative
myeloid progenitors was evaluated in the colony-forming cell assay
(Table 2, Figure 3). Being the most immature of the three cell types,
the CMPs gave rise to both myeloid, erythroid and CFU-GEMM
colonies in both the CLEC12A+ and CLEC12A subsets. The total
number of colonies was significantly higher in the seeded CLEC12A
CMPs (P = .02). Moreover, significantly fewer erythroid colonies
were observed in the seeded CLEC12A+ CMP subset (P = .002),
showing that CLEC12A positivity favours a non-erythroid lineage.
For both CLEC12A+/ GMPs, the clonogenic growth was almost
exclusively of myeloid origin and no CFU-GEMMs were evident
(Table 2), which is in accordance with the original definition of this
cell subset.22 We found no difference neither in the overall clono-
genic potential of the CLEC12A+ and CLEC12A GMPs (P = .31) nor
in the distribution of the different myeloid colonies between the
CLEC12A+/ GMPs (CFU-GM (P = .33); CFU-M (P = .79); CFU-G
(P = .08)). With respect to MEPs, where the expected read out
would be colonies of erythroid origin, we found that the CLEC12A+
MEPs predominantly gave rise to myeloid colonies (on average
79.8%) and the number of erythroid colonies was significantly lower
among the seeded CLEC12A+ MEP subset compared to the
CLEC12A MEP subset (P = .002), indicating these particular cells to
represent a non-MEP progenitor. The read out of CLEC12A MEPs
was almost exclusively erythroid (on average 96.8%) as would be
expected of true MEPs (Table 2). This indicates that adding
CLEC12A could be useful in distinguishing true erythroid progenitors
from cells with myelomonocytic potential. In conclusion, the CFU-
assays demonstrated heterogeneity in the CMP and MEP progenitor
subsets when adding the CLEC12A marker to the sorting scheme
with CLEC12A+ progenitors favouring colonies of the myelomono-
cytic lineage.
4 | DISCUSSION
This data set confirms the observation of normal CD34+CD38 cells
lacking the CLEC12A marker (Table S1, Figure S1), and by including
a detailed delineation of the myeloid CD34+CD38+ progenitors, we
have extended the seminal findings by van Rhenen et al.2 We
demonstrated the consistently distinct expression of CLEC12A at
the level of the classically defined CMPs, GMPs and MEPs with the
F IGURE 2 Distribution of CLEC12A+
cells in myeloid progenitors. Percentage of
CLEC12A+ cells in CMP, GMP and MEP in
BM from 13 healthy donors. Horizontal bars
denote the mean. The P-value applies to all
three comparisons (A). Overlay of the
CLEC12A+ cell population on the Lin-
CD34+CD38CD90 cells displayed in a
CD45RA vs. CD123 plot showing the
distribution of the CLEC12A+ progenitors (B)
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marker emerging at the level of the CMP, being abundantly
expressed on the GMP subset and to a lesser extent on the pheno-
typically defined MEPs. By investigating the CLEC12A positive and
negative progenitors in the colony-forming cell assay, we further-
more provided evidence of functional differences particularly in the
CMP and MEP subsets, where CLEC12A positivity favoured colony
growth of myelomonocytic lineage.
Importantly, our findings could add to the deeper understanding
of CLEC12A as a blast- and cancer stem cell marker in the spectrum
of myeloid neoplasms. Acute myeloid leukaemia has to a large extent
served as a model for studying disease-propagating cells,25 and while
the first publications indicated the LSC to immunophenotypically
resemble the normal CD34+CD38 HSC,26,27 recent research has
indicated most cases of AML to propagate from the progenitor com-
partment with functional LSC activity in cells resembling the MLP16
and for CD34- AML even more mature progenitors/precursors.15,28
In addition, in low-risk myelodysplastic syndrome (MDS), the cancer
stem cells have been shown to reside in the HSC compartment,13
although studies on high-risk MDS indicate the MDS-propagating
cell to arise in the MPP or GMP compartment, much resembling
AML.29,30 In this context, the likely usefulness of CLEC12A as a mar-
ker of the leukaemic blasts and/or stem cells could be linked to the
fact that the level of differentiation arrest occurs in a cell type natu-
rally expressing this marker. By inference—regarding CLEC12A as a
marker of myeloid progenitors and their downstream progeny—the
presence of CLEC12A on AML blasts and stem cells could indicate a
myeloid progenitor/precursor disease, while CLEC12A AML could
correspond to a more immature stem cell disease originating from a
cell at the level of the CLEC12A CMP or upstream. In accordance
with this, CLEC12A expression on AML blasts is highly correlated
with CD34 negativity,1 which is often associated with a more mature
subtype of AML.15 Whether CLEC12A expression on leukaemic
blasts has prognostic impact in CD34+ AML remains to be eluci-
dated. Future studies are warranted to explore this in detail and also
to examine whether the aberrant expression of CLEC12A on
CD34+CD38 cells shown in some cases of AML2,4 and MDS6 is
due to an up-regulation of CLEC12A in these early stem/progenitor
cells or a down-regulation of CD38 in the leukaemic CLEC12A+
cells.
Our data impact on the notion of CLEC12A as a druggable pro-
tein in myeloid malignancies, where the first open-label, first-in-
human phase 1 study of a bispecific CLEC12A-CD3 antibody has
been initiated in Europe (EudraCT number 2015-003704-23). Thus,
while such a treatment will most likely spare the earliest
haematopoietic stem and progenitor cells (the Lin-CD34+CD38 cell
subset) and thereby not affect long-term haematopoiesis, this study
provides evidence that approximately 60% of CMPs together with
progenitors capable of maintaining the erythroid and—although not
addressed in this work—megakaryocyte lineages will also remain
unaffected by such approaches. On the other hand, given that
more than 80% of GMPs would be expected to be eradicated, it
cannot be excluded that a pronounced and long-lasting depletion of
functional neutrophils would follow. While CLEC12A is expressed
on mature eosinophilic- and basophilic granulocytes,24,31 our study
did not include a functional evaluation of the eosinophil and baso-
phil potential of the CLEC12A+/ myeloid progenitors; hence, a
prediction of how CLEC12A directed therapy would affect these
cell types cannot be made. In addition, our results cannot formally
TABLE 2 Colony distribution of cultured myeloid progenitor subsets
CFU type
CLEC12A subset CLEC12A+ subset
P-value
Median number of colonies/
100 cells plated (range) %
Median number of colonies/
100 cells plated (range) %
CMP
Total 32.9 (24.4-46.0) 100 25.6 (13.7-31.2) 100 .02
CFU-GEMM 1.3 (0.6-2.8) 4.0 0.45 (0-2.2) 2.3 .18
Myeloid 15.1 (12.8-29.2) 48.4 16.6 (8.3-20.2) 66.5 .90
Erythroid 16.5 (10.1-25.6) 47.6 8.8 (3.0-9.3) 31.2 .002
GMP
Total 15.8 (9.3-23.7) 100 19.8 (16.9-23.3) 100 .31
CFU-GEMM 0.0 (0.0-0.0) 0.0 0.0 (0.0-0.0) 0.0 -
Myeloid 15.8 (9.3-23.4) 99.8 19.8 (16.9-23.1) 99.9 .31
Erythroid 0.0 (0.0-0.3) 0.2 0.0 (0.0-0.2) 0.1 >.99
MEP
Total 32.5 (16.5-39.2) 100 24.5 (15.2-38.9) 100 .79
CFU-GEMM 0.0 (0.0-0.2) 0.1 0.0 (0.0-0.0) 0 >.99
Myeloid 0.7 (0.5-1.8) 3.2 20.2 (15.2-29.6) 79.8 .002
Erythroid 31.5 (15.7-38.6) 96.8 6.5 (0.0-13.3) 20.2 .002
CMP, common myeloid progenitor; GMP, granulocyte-macrophage progenitor; MEP, megakaryocyte-erythroid progenitor; CFU, colony forming unit.
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rule out the possibility that CLEC12A could be expressed at low
levels intracytoplasmic in possible myeloid primed early
CD34+CD38 haematopoietic stem- and progenitor cells. In fact,
novel insights into human haematopoiesis question the existence of
true oligo- and bipotent progenitors.32 Nevertheless, as new tar-
geted treatment strategies directed towards surface proteins are
continuously evolving, most recently supplemented with the excit-
ing development of chimeric antigen receptor (CAR)-engineered T
cells (CAR-T cells) directed against CLEC12A,33,34 detailed knowl-
edge of the surface expression of this receptor remains important
in a translational setting.
Based on our findings showing a highly differentiated expres-
sion of CLEC12A on the classically defined myeloid progenitors,
we propose CLEC12A could be a helpful marker to add in future
detailed studies of the early human haematopoiesis. The technical
advances in flow cytometry allowing the addition of more surface
markers combined with novel RNA sequencing techniques and
functional assays at the single cell level have opened new doors
to study haematopoiesis.35 Indeed, Kawamura et al recently
applied CLEC12A together with CD64 to study the early mono-
cytic differentiation at the level of GMPs.36 In further support of
adding CLEC12A in the studies of human haematopoiesis, Drissen
et al studied murine myeloid differentiation pathways performed
with RNA sequencing of 63 single pre-granulocyte-macrophage
cells, and interestingly, CLEC12A turned up as a potential subpop-
ulation classifier being one of the 55 genes showing differential
expression by cluster analysis and proved to be mutually exclusive
with GATA1.37 In this study, the GATA1+ (and thereby
F IGURE 3 Colony-forming cell assays on CLEC12A+/ CMPs, GMPs and MEPs from 6 normal donors. Asterisk (*) denotes mean number of
colonies from plates seeded in doublets.
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CLEC12A) cells gave rise to mast cells and eosinophils, while the
GATA1 (CLEC12A+) cells gave rise to monocytes and neutrophils
—cells that are also known to express CLEC12A in humans.23,24,37
Interestingly, by adding the surface markers CD71 and BAH-1 to
the established sorting schemes of myeloid progenitors, a study
by Notta and colleagues found the originally defined CMPs to be
quite heterogeneous and to consist of unipotent myeloid and ery-
throid progenitors with very sparse megakaryocyte activity.11 In
line with this, our data indicate that adding CLEC12A as a de-
selection marker in the sorting scheme of MEPs could purify the
early erythroid subset further.
In conclusion, we here show the differentiated expression of
CLEC12A at the level of myeloid progenitors and provide evidence
that the earliest CLEC12A+ cell in the haematopoietic tree is the
classically defined CMP. While this knowledge is readily translational
in the setting of CLEC12A-targeted treatment, we also suggest that
the marker is continuously explored in basic research studying the
early myeloid differentiation.
ACKNOWLEDGEMENTS
The authors gratefully acknowledge Professor Gordon D. Brown,
MRC Centre for Medical Mycology, University of Aberdeen, for pro-
viding the anti-CLEC12A hybridoma. The Danish Cancer Society and
The Meyer Foundation supported the study.
AUTHOR CONTRIBUTIONS
M.B., L.N., P.B.v.K.N., P.W. and P.H. designed the study. M.B., L.L.H.
and L.N. performed the experiments. M.B. and L.N. analysed the
data. M.B. drafted the manuscript and received input and critical
reviews from L.N., P.B.v.K.N., P.H., P.W. and A.S.R.. P.H. provided
the financial background for the study. All authors read and
approved the final manuscript.
CONFLICT OF INTERESTS




1. Larsen HØ, Roug AS, Just T, Brown GD, Hokland P. Expression of
the hMICL in acute myeloid leukemia-a highly reliable disease marker
at diagnosis and during follow-up. Cytometry B Clin Cytom.
2012;82:3-8.
2. van Rhenen A, van Dongen GAMS, Kelder A, et al. The novel AML
stem cell associated antigen CLL-1 aids in discrimination between
normal and leukemic stem cells. Blood. 2007;110:2659-2666.
3. van Rhenen A, Moshaver B, Kelder A, et al. Aberrant marker expres-
sion patterns on the CD34 + CD38- stem cell compartment in acute
myeloid leukemia allows to distinguish the malignant from the nor-
mal stem cell compartment both at diagnosis and in remission. Leuke-
mia. 2007;21:1700-1707.
4. Terwijn M, Zeijlemaker W, Kelder A, et al. Leukemic stem cell
frequency: a strong biomarker for clinical outcome in acute myeloid
leukemia. PLoS ONE. 2014;9:e107587.
5. Roug AS, Larsen HØ, Nederby L, et al. hMICL and CD123 in combi-
nation with a CD45/CD34/CD117 backbone - a universal marker
combination for the detection of minimal residual disease in acute
myeloid leukaemia. Br J Haematol. 2014;164:212-222.
6. Toft-Petersen M, Nederby L, Kjeldsen E, et al. Unravelling the rele-
vance of CLEC12A as a cancer stem cell marker in myelodysplastic
syndrome. Br J Haematol. 2016;175:393-401.
7. Zhao X, Singh S, Pardoux C, et al. Targeting C-type lectin-like mole-
cule-1 for antibody-mediated immunotherapy in acute myeloid leu-
kemia. Haematologica. 2010;95:71-78.
8. Lu H, Zhou Q, Deshmukh V, et al. Targeting human C-type lectin-like
molecule-1 (CLL1) with a bispecific antibody for immunotherapy of
acute myeloid leukemia. Angew Chem Int Ed Engl. 2014;53:9841-
9845.
9. Leong SR, Sukumaran S, Hristopoulos M, et al. An anti-CD3/anti-
CLL-1 bispecific antibody for the treatment of acute myeloid leuke-
mia. Blood. 2017;129:609-618.
10. Woolthuis CM, Park CY. Hematopoietic stem/progenitor cell com-
mitment to the megakaryocyte lineage. Blood. 2016;127:1242-1248.
11. Notta F, Zandi S, Takayama N, et al. Distinct routes of lineage devel-
opment reshape the human blood hierarchy across ontogeny. Science
2016;351:aab2116.
12. G€orgens A, Radtke S, M€ollmann M, et al. Revision of the human
hematopoietic tree: granulocyte subtypes derive from distinct
hematopoietic lineages. Cell Rep. 2013;3:1539-1552.
13. Woll PS, Kj€allquist U, Chowdhury O, et al. Myelodysplastic syn-
dromes are propagated by rare and distinct human cancer stem cells
in vivo. Cancer Cell. 2014;25:794-808.
14. Chesnais V, Arcangeli M-L, Delette C, et al. Architectural and func-
tional heterogeneity of hematopoietic stem/progenitor cells in non-
del(5q) myelodysplastic syndromes. Blood. 2017;129:484-496.
15. Quek L, Otto GW, Garnett C, et al. Genetically distinct leukemic
stem cells in human CD34- acute myeloid leukemia are arrested
at a hemopoietic precursor-like stage. J Exp Med. 2016;213:1513-
1535.
16. Goardon N, Marchi E, Atzberger A, et al. Coexistence of LMPP-like
and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer
Cell. 2011;19:138-152.
17. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of prim-
itive human hematopoietic cells capable of repopulating immune-
deficient mice. Proc Natl Acad Sci USA. 1997;94:5320-5325.
18. Conneally E, Cashman J, Petzer A, Eaves C. Expansion in vitro of
transplantable human cord blood stem cells demonstrated using a
quantitative assay of their lympho-myeloid repopulating activity in
nonobese diabetic-scid/scid mice. Proc Natl Acad Sci USA.
1997;94:9836-9841.
19. Lansdorp PM, Sutherland HJ, Eaves CJ. Selective expression of
CD45 isoforms on functional subpopulations of CD34 + hemopoi-
etic cells from human bone marrow. J Exp Med. 1990;172:363-366.
20. Majeti R, Park CY, Weissman IL. Identification of a hierarchy of mul-
tipotent hematopoietic progenitors in human cord blood. Cell Stem
Cell. 2007;1:635-645.
21. Doulatov S, Notta F, Eppert K, Nguyen LT, Ohashi PS, Dick JE.
Revised map of the human progenitor hierarchy shows the origin of
macrophages and dendritic cells in early lymphoid development. Nat
Immunol. 2010;11:585-593.
22. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isola-
tion of human clonogenic common myeloid progenitors. Proc Natl
Acad Sci USA. 2002;99:11872-11877.
BILL ET AL. | 2317
23. Bakker ABH, van den Oudenrijn S, Bakker AQ, et al. C-type lectin-
like molecule-1: a novel myeloid cell surface marker associated with
acute myeloid leukemia. Cancer Res. 2004;64:8443-8450.
24. Marshall ASJ, Willment JA, Lin H-H, Williams DL, Gordon S, Brown
GD. Identification and characterization of a novel human myeloid
inhibitory C-type lectin-like receptor (MICL) that is predominantly
expressed on granulocytes and monocytes. J Biol Chem. 2004;279:
14792-14802.
25. Wang JCY, Dick JE. Cancer stem cells: lessons from leukemia. Trends
Cell Biol. 2005;15:494-501.
26. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute
myeloid leukaemia after transplantation into SCID mice. Nature.
1994;367:645-648.
27. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nat
Med. 1997;3:730-737.
28. Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38 anti-
body-mediated clearance of human repopulating cells masks the
heterogeneity of leukemia-initiating cells. Blood. 2008;112:568-575.
29. Dimitriou M, Woll PS, Mortera-Blanco T, et al. Perturbed
hematopoietic stem and progenitor cell hierarchy in myelodysplastic
syndromes patients with monosomy 7 as the sole cytogenetic abnor-
mality. Oncotarget. 2016;7:72685-72698.
30. Rouault-Pierre K, Smith AE, Mian SA, et al. Myelodysplastic syn-
drome can propagate from the multipotent progenitor compartment.
Haematologica. 2017;102:e7-e10.
31. Toft-Petersen M, Stidsholt Roug A, Plesner T, Ebbesen L, Brown
GD, Nederby L. The CLEC12A receptor marks human basophils:
Potential implications for minimal residual disease detection in acute
myeloid leukemia. Cytometry B Clin Cytom. https://doi.org/10.1002/
cyto.b.21540. [Epub ahead of print].
32. Moignard V, G€ottgens B. Dissecting stem cell differentiation using
single cell expression profiling. Curr Opin Cell Biol. 2016;43:78-86.
33. Tashiro H, Sauer T, Shum T, et al. Treatment of acute myeloid leuke-
mia with T cells expressing chimeric antigen receptors directed to
C-type lectin-like molecule 1. Mol Ther. 2017;25:2202-2213.
34. Laborda E, Mazagova M, Shao S, et al. Development of A chimeric
antigen receptor targeting C-type lectin-like molecule-1 for human
acute myeloid leukemia. Int J Mol Sci. 2017;18:E2259.
35. Etzrodt M, Endele M, Schroeder T. Quantitative single-cell
approaches to stem cell research. Cell Stem Cell. 2014;15:546-558.
36. Kawamura S, Onai N, Miya F, et al. Identification of a human
clonogenic progenitor with strict monocyte differentiation poten-
tial: a counterpart of mouse cMoPs. Immunity. 2017;46:835-848.
e4.
37. Drissen R, Buza-Vidas N, Woll P, et al. Distinct myeloid progenitor-
differentiation pathways identified through single-cell RNA sequenc-
ing. Nat Immunol. 2016;17:666-676.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the
supporting information tab for this article.
How to cite this article: Bill M, van Kooten Niekerk PB, Woll
PS, et al. Mapping the CLEC12A expression on myeloid
progenitors in normal bone marrow; implications for
understanding CLEC12A-related cancer stem cell biology.
J Cell Mol Med. 2018;22:2311–2318. https://doi.org/
10.1111/jcmm.13519
2318 | BILL ET AL.
